Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Acer Therapeutics (NASDAQ:ACER – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.
Analyst Ratings
This is a summary of recent ratings and price targets for Amylyx Pharmaceuticals and Acer Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| Acer Therapeutics | 0 | 3 | 0 | 0 | 2.00 |
Amylyx Pharmaceuticals currently has a consensus target price of $49.40, indicating a potential upside of 178.00%. Acer Therapeutics has a consensus target price of $5.00, indicating a potential upside of 563.48%. Given Acer Therapeutics’ higher probable upside, analysts plainly believe Acer Therapeutics is more favorable than Amylyx Pharmaceuticals.
Insider and Institutional Ownership
Profitability
This table compares Amylyx Pharmaceuticals and Acer Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | -37.95% | -23.80% | -20.30% |
| Acer Therapeutics | N/A | -29.93% | 46.17% |
Volatility & Risk
Amylyx Pharmaceuticals has a beta of -0.74, meaning that its share price is 174% less volatile than the S&P 500. Comparatively, Acer Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Valuation and Earnings
This table compares Amylyx Pharmaceuticals and Acer Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $22.23 million | 53.86 | -$198.38 million | ($1.24) | -14.33 |
| Acer Therapeutics | $1.26 million | 14.63 | -$26.24 million | ($0.41) | -1.84 |
Acer Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Acer Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Acer Therapeutics beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Acer Therapeutics
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
